* Kiora Pharmaceuticals Inc reported a quarterly adjusted loss of 81 cents​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of $-8.01. The mean expectation of three analysts for the quarter was for a loss of 76 cents per share. Wall Street expected results to range from -90 cents to -66 cents per share.

* Reported revenue was zero​; analysts expected $7.00 thousand.

* Kiora Pharmaceuticals Inc's reported EPS for the quarter was a loss of 81 cents​.

* The company reported a quarterly loss of $3.41 million.

* Kiora Pharmaceuticals Inc shares had fallen by 2.5% this quarter and lost 24.1% so far this year.

FORECAST CHANGES

* The mean earnings estimate of analysts had fallen by about 11.4% in the last three months.​

* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

* The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Kiora Pharmaceuticals Inc is $27.00 This summary was machine generated from LSEG data November 8 at 08:58 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,

MISSED

Sep. 30 2024 -0.76 -0.81 Missed

Jun. 30 2024 -0.86 -0.53 Beat

Mar. 31 2024 -0.59 3.42 Beat

Dec. 31 2023 -3.77 -4.23 Missed